Healthcare Services

Thyroid Eye Disease (TED) Market Revenue Growth Expected to Reach $3.12 Billion by 2030 with 6.3% CAGR

April 7, 2026April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Thyroid Eye Disease (TED) Market At The End Of The 2026–2030 Forecast Period?

The thyroid eye disease (ted) market size has seen significant growth in recent years. It is forecast to grow from $2.29 billion in 2025 to $2.44 billion in 2026, at a compound annual growth rate (CAGR) of 6.6%. This past expansion can be attributed to the increasing prevalence of autoimmune thyroid disorders, improved clinical recognition of ted symptoms, wider use of corticosteroid therapies, an expansion of ophthalmology services, and growing referral rates from endocrinology clinics.

The thyroid eye disease (TED) market size is anticipated to experience substantial expansion in the coming years. It is forecast to reach $3.12 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This projected growth throughout the forecast period stems from the increasing integration of novel biologics such as teprotumumab, heightened investments in autoimmune disease research, the broadening availability of minimally invasive surgical choices, a growing emphasis on quality-of-life outcomes, and the rising demand for personalized TED therapies. Significant trends expected during this period include the increased adoption of targeted biologic therapies, a greater utilization of combination treatment approaches, an enhanced focus on early disease intervention, the expansion of specialized ophthalmic care, and the development of more patient-centered treatment models.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21300&type=smp

Which Market Drivers Are Supporting The Expansion Of The Thyroid Eye Disease (TED) Market?

An increase in thyroid disorders is projected to fuel the expansion of the Thyroid Eye Disease (TED) market moving ahead. These disorders encompass medical conditions impacting the thyroid gland’s function, causing hormonal imbalances and manifesting as hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The uptick in thyroid disorders is attributed to elements like higher iodine consumption, autoimmune diseases, genetic susceptibility, and enhanced awareness resulting in better diagnostic figures. Thyroid Eye Disease (TED) itself adds to the growing number of thyroid disorder instances, being a frequent and severe complication of Graves’ disease, thereby elevating the total impact and recognition of thyroid-associated ailments. For example, data from May 2024, provided by the Canadian Cancer Society, a Canada-based non-profit community organization, forecasts around 6,600 new thyroid cancer diagnoses in Canada during 2024, along with an estimated 280 deaths. Consequently, the escalation of thyroid disorders is a key impetus for the expansion of the Thyroid Eye Disease (TED) market.

What Segment Types Make Up The Thyroid Eye Disease (TED) Market?

The thyroid eye disease (ted) market covered in this report is segmented –

1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical

2) By Disease Severity: Mild, Moderate, Severe

3) By Drug Type: Biologics, Small Molecules, Other Drug Types

4) By Route Of Administration: Oral, Intravenous, Subcutaneous

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications

2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery

3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery

What Key Trends Are Influencing The Development Of The Thyroid Eye Disease (TED) Market?

Leading companies within the thyroid eye disease (TED) market are concentrating on innovative products, such as monoclonal antibody therapies, to develop more effective, targeted treatments aimed at reducing inflammation, improving proptosis, and enhancing overall patient outcomes. Monoclonal antibody therapies are treatments utilizing laboratory-made antibodies designed to mimic the immune system’s capability to target and neutralize specific pathogens or abnormal cells. For instance, in September 2024, Amgen Inc., a US-based biotechnology company, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) had approved TEPEZZA (teprotumumab) for addressing active thyroid eye disease (TED), a rare and potentially vision-threatening autoimmune disorder. This is the first and only FDA-approved therapy specifically for TED, providing a targeted treatment that assists in reducing inflammation, swelling, and other debilitating symptoms linked to the condition. This approval holds particular importance for patients in Japan, as it offers a new, effective choice to manage TED, a rare and progressive condition that results in debilitating eye bulging, vision issues, and eye pain.

Who Are The Key Players Driving Competition In The Thyroid Eye Disease (TED) Market?

Major companies operating in the thyroid eye disease (ted) market are Viridian Therapeutics Inc, Tourmaline Bio Inc, Sling Therapeutics Inc, Immunovant Inc, Hoffmann-La Roche AG, H Lundbeck A S, Alumis Inc, Changchun GeneScience Pharmaceutical Co Ltd, Minghui Pharmaceutical Inc, Amgen Inc, Crinetics Pharmaceuticals Inc, Ollin Biosciences Inc, Lycia Therapeutics Inc, Inflammasome Therapeutics Inc, Novartis Pharmaceuticals Corp, AdvanceCOR Inc, Worg Pharmaceuticals Inc, AV7 Limited, EVOQ Therapeutics Inc, ValenzaBio Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sanofi SA, Alexion Pharmaceuticals Inc, Septerna Corporation

Read the full thyroid eye disease (ted) market report here:

https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report

How Is The Thyroid Eye Disease (TED) Market Distributed Across Key Geographic Regions?

North America was the largest region in the thyroid eye disease (TED) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (ted) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Thyroid Eye Disease (TED) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21300&type=smp

Browse Through More Reports Similar to the Global Thyroid Eye Disease (TED) Market 2026, By The Business Research Company

Eye Melanoma Global Market Report

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Thyroid Function Test Global Market Report

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Thyroid Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795